Did you know?

One person is diagnosed with a blood clot every minute. One person dies from a blood clot every six minutes.

News & Events

Patient education video now online more...

World Thrombosis Day is October 13 more...

Upcoming event: Walk to increase awareness of thrombosis in infants and children more...

Venous Thromboembolism Resource 

Deep vein thrombosis (DVT) & Pulmonary embolism (PE)

Clot Connect is an information and outreach project at the University of North Carolina at Chapel Hill Hemophilia and Thrombosis Center. Clot Connect provides patients and healthcare professionals connection to clinically relevant education resources on deep vein thrombosis, pulmonary embolism, thrombophilia and anticoagulation.   


Newly diagnosed with deep vein thrombosis (DVT) or pulmonary embolism (PE)?  

Start your search for information here.  

From our Patient Blog

Athletes and Blood Clots

Can Athletes With DVT or PE Return To Play? Fact-Based Rather Than Emotional Reasoning   Stephan Moll, MD1, Joshua Berkowitz, MD2, Philip Blatt, MD, FACP3   Every so often news hit the media that a prominent athlete has had a blood clot: NBA athlete Chris Bosh and NHL’s Steven Stamkos most recently, NBA’s Mirza Teletović and […] Read the rest of this entry »

From our Healthcare Professionals Blog

Athletes and Blood Clots

Stephan Moll, MD writes: Athletes with DVT or PE and on anticoagulation face significant challenges returning to full athletic activities. A recent publication of the American College of Cardiology discusses individualized management regimens that may return athletes to return to their sport – http://www.bit.ly/2erRLc0.   Last updated: Oct 30th, 2016 Read the rest of this entry »

NO FDA Approval Yet for Andexanet

Stephan Moll, MD writes… The FDA did NOT approve Andexanet (brand names: AndexXa™ in the US, IndexXa™ in Europe) in a decision on August 18th, 2016.  Andexanet is the antidote in clinical development to reverse the anticoagulant effect of Eliquis® (rivaroxaban), Savaysa® (edoxaban), Xarelto® (rivaroxaban) and Lovenox® (enoxaparin).  The FDA is said to have requested more information from […] Read the rest of this entry »